Alpha Tau Medical Ltd ((DRTS)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alpha Tau Medical Ltd (DRTS) is currently recruiting for a clinical study titled A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer. The primary objective is to evaluate the safety of Alpha DaRT in combination with chemotherapy, focusing on adverse events. Secondary objectives include assessing efficacy, pain control, and surgical resection rates.
The intervention being tested is the Diffusing Alpha Radiation Emitters Therapy (DaRT), a device designed to release short-lived alpha-emitting atoms directly into tumors, used alongside chemotherapy to treat pancreatic cancer.
This interventional study is non-randomized with a parallel assignment model, involving two cohorts of 15 patients each. It is open-label with no masking, and its primary purpose is treatment.
The study began on June 17, 2025, with the last update on June 30, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
For investors, this study could influence Alpha Tau Medical’s stock performance, especially if the results show significant safety and efficacy. The company’s advancements in cancer treatment could position it favorably against competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.